LumiraDx Limited (LMDX) Stock

About LumiraDx Limited

LumiraDx Limited is a prominent provider of point-of-care diagnostic solutions. Its core mission is to revolutionize community healthcare by equipping medical professionals with crucial diagnostic insights directly at the patient's side. The company develops and commercializes a sophisticated diagnostic platform, offering a diverse array of tests that deliver laboratory-grade performance directly at the point of care. With approximately 30 tests either commercially available or under development, their comprehensive portfolio addresses critical conditions such as infectious diseases, cardiovascular disorders, diabetes, and coagulation issues. Furthermore, they offer a full suite of COVID-19 testing solutions, adaptable for both laboratory environments and immediate point-of-need applications. These diagnostic tools are widely adopted by governments and healthcare institutions, deployed in diverse settings including traditional laboratories, urgent care clinics, physician's offices, pharmacies, schools, and workplaces. Their applications span screening, diagnosis, and monitoring for both general wellness and specific diseases. Established in 2014, the company's headquarters are located in London, United Kingdom.

LumiraDx Limited is headquartered in GB.

LumiraDx Limited (LMDX) stock trades at $0.02 with a market capitalization of $5.10M. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of -0.04, price-to-sales of 0.02. Over the past 52 weeks the stock has ranged between $0.02 and $0.03, and currently trades 33.3% below its 52-week high.

On profitability, LumiraDx Limited generates a return on equity (ROE) of 427.62% — well above the market average, a sign of a high-quality business, return on capital employed of -92.05%, an operating margin of -126.32%, a net profit margin of -176.52%.

Official website: www.lumiradx.com